StockNews.AI
PETS
StockNews.AI
64 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc. - PETS

1. Pomerantz LLP investigates PetMed Express for possible securities fraud. 2. PetMed delayed its fiscal year 2025 earnings release and call. 3. Stock fell 11.22% to $3.72 following the earnings delay announcement. 4. Investors can join a class action related to the investigation. 5. Pomerantz has a notable history in corporate class action litigation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The delay in earnings and possible securities fraud raises significant investor concern, reminiscent of situations in similar companies facing legal challenges, such as Valeant Pharmaceuticals in the past, which resulted in steep price declines due to loss of investor confidence and ongoing investigations.

How important is it?

The ongoing investigation and earnings release delay directly affect current investor sentiment and trust in PetMed, which can heavily weigh on stock performance.

Why Short Term?

The immediate market response shows high sensitivity to news; stock volatility can continue until clarity on the legal action emerges, drawing parallels to cases like Tesla's operational delays impacting short-term price action.

Related Companies

WOOFCHWYCADLCVS
Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ:PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether PetMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On June 10, 2025, PetMed issued a press release "announc[ing] it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process."On this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.Attorney advertising. Prior results do not guarantee similar outcomes.SOURCE: Pomerantz LLP

Related News